help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on February 1, 2007, doi:10.1164/rccm.200611-1615OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200611-1615OCv1
175/8/846    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kerbaul, F.
Right arrow Articles by Naeije, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kerbaul, F.
Right arrow Articles by Naeije, R.
American Journal of Respiratory and Critical Care Medicine Vol 175. pp. 846-850, (2007)
© 2007 American Thoracic Society
doi: 10.1164/rccm.200611-1615OC


Original Article

How Prostacyclin Improves Cardiac Output in Right Heart Failure in Conjunction with Pulmonary Hypertension

François Kerbaul*,1, Serge Brimioulle*,2, Benoît Rondelet1, Céline Dewachter1, Ives Hubloue1 and Robert Naeije1

1 Laboratory of Physiology, Faculty of Medicine of the Free University of Brussels, Brussels, Belgium; and 2 Department of Intensive Care, Erasme University Hospital, Brussels, Belgium

Correspondence and requests for reprints should be addressed to Dr. R. Naeije, M.D., Ph.D. Department of Physiology, Faculty of Medicine of the Free University of Brussels, Erasme Campus, CP 604, Lennik Road 808, B-1070 Brussels, Belgium. E-mail: rnaeije{at}ulb.ac.be

Rationale: Prostacyclin therapy improves patients with pulmonary arterial hypertension, but whether this is attributable to an improved inotropic state of the right ventricle in addition to a decreased pulmonary arterial pulmonary vascular resistance remains unclear.

Objectives: We measured the effects of prostacyclin on load-independent measurements of right ventricular contractility in a model of load-induced acute right ventricular failure.

Methods and Results: Persistent right ventricular failure was induced in dogs by a transient (90 min) pulmonary arterial constriction. After constriction release and stabilization, intravenous prostacyclin (epoprostenol) was given at doses of 6 and 12 ng/kg/minute for 30 minutes. Pulmonary vascular resistance was assessed by pressure–flow relationships and right ventricular afterload by effective pulmonary arterial elastance. Right ventricular contractility was estimated by end-systolic elastance and right ventriculoarterial coupling efficiency by the ratio of these elastances. Transient pulmonary arterial constriction persistently increased pulmonary vascular resistance, increased arterial elastance from 1.00 ± 0.07 to 2.86 ± 0.26 mm Hg/ml, decreased end-systolic elastance from 1.11 ± 0.07 to 0.54 ± 0.02 mm Hg/ml, decreased the ratio of elastances from 1.14 ± 0.08 to 0.20 ± 0.02, and cardiac output from 4.6 ± 0.1 to 2.3 ± 0.1 L/min (p < 0.05). Epoprostenol did not affect end-systolic elastance; however, it decreased arterial elastance to 1.84 ± 0.33 mm Hg/ml, and increased the ratio of elastances to 0.46 ± 0.17 and cardiac output to 3.4 ± 0.3 L/min (p < 0.05).

Conclusions: In this model of afterload-induced right ventricular failure, prostacyclin improves right ventriculoarterial coupling and cardiac output because of vasodilating effects.

Key Words: right heart failure • contractility • heart failure • pulmonary hypertension • prostaglandins


AT A GLANCE COMMENTARY

Scientific Knowledge on the Subject
Prostacyclin improves pulmonary arterial hypertension, but whether this is partly explained by positive inotropic effects remains unclear.

What This Study Adds to the Field
In experimental afterload right heart failure, prostacyclin improves cardiac output and right ventricular contractility because of vasodilating effects.

 



This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
D. B. Badesch, H. C. Champion, M. A. Gomez Sanchez, M. M. Hoeper, J. E. Loyd, A. Manes, M. McGoon, R. Naeije, H. Olschewski, R. J. Oudiz, et al.
Diagnosis and assessment of pulmonary arterial hypertension.
J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S55 - S66.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M. Gomberg-Maitland and H. Olschewski
Prostacyclin therapies for the treatment of pulmonary arterial hypertension
Eur. Respir. J., April 1, 2008; 31(4): 891 - 901.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. Humbert
Update in Pulmonary Arterial Hypertension 2007
Am. J. Respir. Crit. Care Med., March 15, 2008; 177(6): 574 - 579.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2007 American Thoracic Society
  CCM abstracts